在儿童中治疗神经精神疾病:实际考虑
D Dilara Ertenu1, Jay A Salpekar1,2
1Neuropsychiatry Program, Kennedy Krieger Institute, Baltimore, MD, USA.
Epilepsy currents
|June 19, 2025
概括
本综述为患有同时出现抑郁症,行为问题或注意力缺陷/多动症障碍 (ADHD) 的年轻人开始服用症药物提供了指导. 它有助于临床医生优化神经和精神病治疗,以获得更好的患者结果.
科学领域:
- 儿科神经学 儿科神经学
- 儿童精神病学 儿童精神病学
- 临床药理学 临床药理学
背景情况:
- 经常与儿童和青少年的神经精神疾病同时发生.
- 管理这些并发症带来了重大的临床挑战.
- 现有的指导方针往往缺乏针对这种复杂人群的药理学启动的具体建议.
研究的目的:
- 提出一个实用的,以证据为基础的框架,用于在患有并发性神经精神病症状的儿科患者中开始药理治疗.
- 为临床医生在药物选择,启动和监测方面提供指导.
- 为了优化这个患者群体的神经和精神病的结果.
主要方法:
- 这是一篇综述性文章,综合了当前的证据和临床最佳实践.
- 该方法侧重于决定药物必要性的决策标准.
- 讨论了心理和抗药物选择和管理的关键考虑因素.
主要成果:
- 该审查概述了确定何时需要药理干预的具体标准.
- 它为选择合适的药物提供了指导,并考虑了潜在的相互作用和副作用.
- 详细介绍了安全有效的药物启动和持续监测的一般原则.
结论:
- 一种结构化,基于证据的方法对于管理年轻人患有伴随性神经精神疾病症状的至关重要.
- 优化药理疗法需要仔细考虑神经和精神方面.
- 拟议的框架旨在改善临床决策和改善患者的治疗结果.
相关概念视频
Epilepsy and Seizures: Overview
296
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
296
Antiepileptic Drugs: Glutamate Antagonists
527
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
527
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
461
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
461
Antiepileptic Drugs: GABAergic Pathway Potentiators
681
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
681
Psychosis: Goals of Pharmacotherapy
214
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
214
Electroconvulsive Therapy
205
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
205


